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transforming factor  neu , hepatocyte growth 
factor, retinoic acid, glucocorticoids, and 
nuclear factor-  B. The overexpressed 
NGAL protein binds to MMP-9, thereby 
preventing MMP-9 degradation and 
increasing MMP-9 enzyme activity. In turn, 
MMP-9 activity promotes cancer progres-
sion by degrading the basement mem-
branes and extracellular matrix, liberating 
VEGF, and thus enabling angiogenesis, 
invasion, and metastasis. Paradoxically, 
recent studies in several tumor cell lines 
have shown that NGAL enhanced the epi-
thelial phenotype, reduced tumor growth, 
and suppressed metastasis; this prosurvival 
activity of NGAL is mediated by its ability 
to bind and transport iron inside the cells. 9 
Especially pertinent to the study by Porta 
 et al. 3 are recent fi ndings that (1) NGAL is 
induced by hypoxia and may indeed be 
driven by the pro-neoplastic hypoxia-
inducible factor-1  (HIF-1  ), which in 
turn is regulated by  VHL ; (2) NGAL can 
inhibit HIF-1  ; and (3) NGAL can inhibit 
VEGF synthesis. 
 How does one reconcile the seemingly 
contradictory roles of NGAL in human 
biology? A potentially unifying hypoth-
esis is off ered in  Figure 1 . Effi  cient mech-
anisms have evolved for the intracellular 
uptake of NGAL via receptors such as 
megalin, and for intracellular traffi  cking 
via endosomes. Th e subsequent molecu-
lar path taken by NGAL may be largely 
dependent on the type of molecule it is 
complexed with. NGAL that is devoid of 
siderophore and iron (holo-NGAL) rap-
idly scavenges intracellular iron. The 
resultant intracellular iron depletion 
results in a decrease in the mammalian 
cell ’ s proliferative ability and in induc-
tion of apoptosis. On the other hand, 
when NGAL is bound to siderophore 
and iron, there is a rapid release of iron 
with regulation of iron-dependent 
molecular pathways and downstream 
induction of proliferation and epithelial 
transformation. Finally, when NGAL is 
complexed with MMP-9 instead, there is 
enhancement of the active MMP-9 pool 
with resultant upregulation of MMP-9 ’ s 
well-known proangiogenic and proinva-
sive properties. Future studies aimed at 
further testing these hypotheses hold 
promise for advancing our understand-
ing of tumor biology, and for potentially 
validating NGAL as a biomarker for per-
sonalizing renal cancer care. 
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 LECT2 amyloidosis 
 Merrill D.  Benson 1 
 LECT2 amyloidosis is the latest systemic type of amyloidosis to be 
described. It was discovered in patients with nephrotic syndrome and 
renal failure and is characterized by amyloid deposition in glomeruli, 
renal vessels, and interstitium. Clinical and pathological features of 
earlier phases of this type of amyloidosis have yet to be determined. 
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 In 1971 Glenner  et al. reported the amino 
acid structure of monoclonal immuno-
globulin light chain (AL) protein isolated 
from tissues of a patient with primary 
amyloidosis. 1 Th is was the fi rst human 
amyloid protein to be chemically charac-
terized. Structural characterization of 
human secondary amyloid protein (serum 
amyloid A (SAA)) was soon to follow in 
1972, 2 and since then, eight additional 
proteins associated with human systemic 
amyloidosis have been identified, for a 
total of ten ( Table 1 ). Th e latest of these 
amyloid proteins is leukocyte chemotactic 
factor 2 (LECT2), which, so far, appears 
mainly to cause renal amyloidosis. 3 
 LECT2 amyloid was originally discov-
ered in a patient who had nephrotic syn-
drome and slowly progressive renal failure 
over a number of years ( Figure 1 ). Clinical 
evaluation and renal biopsy studies failed 
to determine the type of amyloidosis, and 
only when the patient developed renal-cell 
carcinoma, which necessitated nephrec-
tomy, did amyloid-laden tissue become 
available for biochemical analysis. With-
out this chain of events and the inquisitive 
mind of the renal pathologist, it is unlikely 
that the correct diagnosis for this patient 
would have been made, and LECT2 
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 amyloidosis would have remained 
unknown for some longer period of time. 
At first it appeared that this first case 
might be an isolated phenomenon and not 
of signifi cant importance in clinical neph-
ropathology. Now that we have seen addi-
tional cases, and in light of the report by 
Larsen  et al. 4 (this issue), we can project 
that LECT2 amyloidosis will be an impor-
tant entity to consider in seeking a diag-
nosis for renal disease. Th is is a good time 
for us to take a few minutes and contem-
plate what we do know and what we do 
not know about this newly discovered 
type of amyloidosis. 
 First we should realize that LECT2 has 
been discovered in cases of renal amy-
loidosis in which no defi nitive diagnosis 
had been made for extended periods of 
time. Th e fi rst couple of patients to come 
to our attention had had nephrotic syn-
drome for at least 2 years, and renal biop-
sies displayed advanced amyloid 
deposition. Th e original report and the 
report by Larsen  et al. 4 point out what 
appear to be distinguishing histological 
features for LECT2 amyloidosis, namely, 
prominent congophilia and involvement 
of not only glomeruli but also vascular and 
interstitial structures. Th is is probably not 
the case for early stages of the disease. One 
question that we need to address as we 
accumulate more cases is whether glomer-
ular basement membrane deposition 
occurs fi rst or whether there is substantial 
amyloid deposition in blood vessel walls 
and / or interstitial deposition early in the 
course of the disease. Th is will be impor-
tant if we are to accurately evaluate renal 
biopsies and make a timely diagnosis for 
patients with this type of amyloidosis. 
 Table 1  |  Human systemic amyloidosis 
proteins 
 Fibril proteins 




light chain (AL) 
 1971 
 Amyloid A (AA)  1972 
 Transthyretin  1981 
 Cystatin C  1986 
 Apolipoprotein A-I  1988 
 Gelsolin  1990 
 Fibrinogen A  -chain  1993 
 Lysozyme  1993 
 Apolipoprotein A-II  2001 
 LECT2  2008 
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 Figure 1  |  Renal histology of LECT2 amyloidosis. ( a ) Renal biopsy from a patient with LECT2 
amyloidosis, showing amyloid deposits in glomeruli, blood vessel walls, and tubular interstitium. 
(Congo red stain; originval magnification,  × 100.) ( b ) Same section as in panel  a , viewed between 
cross-polars, showing characteristic green birefringence of amyloid. ( c ) Immunohistochemical 
staining of renal biopsy in panel  a , stained with anti-LECT2 antibody by an antigen retrieval 
technique at pH2. It should be noted that although immunohistochemistry for LECT2 was 
originally described for sections from frozen tissue, formalin-fixed, paraffin-embedded tissue may 
require antigen retrieval techniques to give positive staining. 
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 Another question is whether LECT2 
amyloidosis is strictly a renal disease or is 
similar to fi brinogen A  -chain hereditary 
amyloidosis, in which renal pathology is 
paramount, but liver, spleen, and even 
cardiac amyloid deposition may be seen 
in later stages, especially if the patient ’ s life 
is extended by renal dialysis. As the story 
of LECT2 amyloidosis evolves, it will be 
necessary to observe the rate of progres-
sion of the renal pathology. For a disease 
for which there is no specifi c therapy, will 
there be a place for renal transplantation, 
such as with apolipoprotein A-I amyloido-
sis, where organ transplantation can give 
a meaningful extension of life? 
 Like all proteins associated with 
systemic amyloidosis, except for SAA, 
LECT2 was well characterized before its 
discovery as an amyloid fi bril precursor 
protein. As its name indicates, LECT2 was 
discovered in studies searching for pro-
teins with leukocyte chemotactic activity. 5 
It was also discovered independently as a 
factor that may be important in restruc-
turing of cartilage and, therefore, was 
named chondromodulin. 6 LECT2 has 
now been accepted as the offi  cial name, 
although further studies on possible bio-
logical properties of the protein suggest 
that LECT2 may be a misnomer. Actually, 
the word  ‘ amyloid ’ is a misnomer, but we 
have all learned to live with this designa-
tion. The true biological function of 
LECT2, if there is one, has yet to be 
determined. While it has leukocyte 
 chemotactic activity  in vitro and may be 
involved in tissue repair, additional stud-
ies have suggested that LECT2 may be 
involved in autoimmune response func-
tions, and structure homology studies 
suggest a possible endopeptidase func-
tion. 7 – 9 Reports of LECT2 induction in 
association with hepatocellular tumors 
raise the question of whether other 
neoplastic processes, such as renal-cell 
carcinoma, can play a role in the patho-
genesis of LECT2 amyloidosis. 10 
 Th e pathogenesis of LECT2 amyloido-
sis remains to be elucidated. All forms of 
amyloidosis are protein folding deposition 
diseases, and a number of factors may be 
at play in the formation and depo sition 
of amyloid fi brils. First it is necessary to 
have a substrate in suffi  cient abundance 
to form clinically signifi cant fi bril depos-
its. Th is is a determining factor in AL 
amyloidosis, in which monoclonal 
immunoglobulin light chains are the 
result of a plasma-cell dyscrasia. In AA 
amyloidosis, increased levels of SAA are 
induced by an infl ammatory response 
and, in susceptible people, lead to amy-
loidosis. In the hereditary forms of amy-
loidosis, genetically determined variant 
forms of plasma proteins are the cause of 
fi bril formation. Although there is no 
evidence that LECT2 amyloidosis is an 
inherited condition, it is of interest that 
the report by Larsen  et al. 4 indicates that 
four of seven cases identifi ed as LECT2 
were in Hispanic subjects. Th e fi rst two 
cases identifi ed in our Amyloid Research 
Laboratories were in patients of Hispanic 
origin. Th erefore, although no obvious 
genetic factor has been identifi ed, there 
may be some genetic predisposition for 
this type of amyloidosis. For LECT2 
there is presently little basis to formulate 
hypotheses on pathogenesis. LECT2 is 
synthesized principally by the liver, and 
it has been shown that increased expres-
sion of LECT2 may occur with hepato-
cellular tumors. It is not yet obvious 
whether increased expression of LECT2 
is a major factor in amyloid formation or 
whether some biological factor involved 
in the metabolism of LECT2 is the insti-
gating factor in the initiation of fi bril 
formation. Th e predilection for renal 
involvement suggests the importance of 
local tissue factors for amyloid fibril 
deposition, but the characteristic appear-
ance of deposits in the glomerular base-
ment membrane, the walls of blood 
vessels, and the tubular interstitium sug-
gests that amyloid deposition may be 
more widespread and involve other 
organs. Future postmortem studies may 
clarify this issue. The structure of an 
amyloid protein obviously is important 
in forming   -fi brils. LECT2 is postulated 
to have extensive   -structure, as do tran-
sthyretin and immunoglobulin light 
chain. Since the entire LECT2 protein 
was found in the fi brils that have been 
analyzed to date, it is unlikely that pro-
teolytic degradation is necessary for 
fi bril formation. It is possible, however, 
that interference in a catabolic pathway 
for LECT2 could lead to increased local 
tissue levels of LECT2 and that this could 
lead to the initiation of fi bril formation 
and deposition. 
 It is always exciting to identify the basis 
of any disease and to be able to see how 
knowledge of its pathogenesis evolves. 
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